OncoTherapy Science (TSE:4564) Net Margin %: -94.39% (As of Mar. 2026)

What is OncoTherapy Science Net Margin %?

OncoTherapy Science TSE:4564 +5.00% 50 Net Margin % is -94.39% as of Mar. 2026. GuruFocus rates TSE:4564 with a GF Score™ of 50/100 and a GF Value™ of 円17.04 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 938 Biotechnology companies, OncoTherapy Science ranks worse than 52.45% on this metric.

Net margin is calculated as Net Income divided by its Revenue. OncoTherapy Science's Net Income for the six months ended in Mar. 2026 was 円-355.5 Mil. OncoTherapy Science's Revenue for the six months ended in Mar. 2026 was 円376.6 Mil. Therefore, OncoTherapy Science's net margin for the quarter that ended in Mar. 2026 was -94.39%.

The historical rank and industry rank for OncoTherapy Science's Net Margin % or its related term are showing as below:

TSE:4564' s Net Margin % Range Over the Past 10 Years
Min: -1349.62 Med: -346.3 Max: -98.57
Current: -112.63

TSE:4564's Net Margin % is ranked worse than
52.45% of 938 companies
in the Biotechnology industry
Industry Median: -88.295 vs TSE:4564: -112.63

OncoTherapy Science (TSE:4564) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

OncoTherapy Science Net Margin % Related Terms

OncoTherapy Science Net Margin % Historical Data

* Premium members only.

The historical data trend for OncoTherapy Science's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoTherapy Science Net Margin % Chart

OncoTherapy Science Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Mar26

Net Margin %

Get a 7-Day Free Trial

-222.90

-98.57

-211.13

-108.70

-112.63

OncoTherapy Science Semi-Annual Data
	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24	Mar25	Sep25	Mar26
Net Margin %	Get a 7-Day Free Trial															-227.65	-242.44	-51.35	-128.53	-94.39

TSE:4564 vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, OncoTherapy Science's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OncoTherapy Science Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoTherapy Science's Net Margin % distribution charts can be found below:

* The bar in red indicates where OncoTherapy Science's Net Margin % falls into.

Save Embed

50GF Score

OncoTherapy Science Inc TSE:4564

Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

OncoTherapy Science Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

OncoTherapy Science's Net Margin for the fiscal year that ended in Mar. 2026 is calculated as

Net Margin	=	Net Income (A: Mar. 2026 )	/	Revenue (A: Mar. 2026 )
	=	-910.638	/	808.53
	=	-112.63 %

OncoTherapy Science's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin	=	Net Income (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-355.507	/	376.639
	=	-94.39 %

Frequently Asked Questions Learn more about Net Margin % →

What does a Net Margin % of -94.39% mean?

OncoTherapy Science (TSE:4564) has a Net Margin % of -94.39% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on OncoTherapy Science and its competitors. According to the industry distribution chart, OncoTherapy Science ranks #492 out of 938 companies in the Biotechnology industry, placing it in the top 52.5%.

Is OncoTherapy Science's Net Margin % too high?

OncoTherapy Science's current Net Margin % is -94.39%. Based on the distribution chart, OncoTherapy Science ranks #492 out of 938 companies in the Biotechnology industry, which is below the industry midpoint. Overall, OncoTherapy Science has a GF Score™ of 50/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does OncoTherapy Science's Net Margin % compare to VRTX and REGN?

According to the Biotechnology industry distribution chart, OncoTherapy Science ranks #492 out of 938 companies for Net Margin %. This places OncoTherapy Science in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Net Margin % for a Biotechnology company?

A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Net Margin % mean?

A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on OncoTherapy Science and its competitors. OncoTherapy Science's current Net Margin % is -94.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is OncoTherapy Science stock overvalued right now?

Based on GuruFocus' analysis, OncoTherapy Science (TSE:4564) is currently considered Modestly Overvalued. The stock's GF Value™ is 円17.04, compared to a current price of 円21.00 — trading 23.2% above its estimated fair value. The current Net Margin % is -94.39%. OncoTherapy Science's overall GF Score™ is 50/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Net Margin % calculated?

Net Margin % is calculated from a company's financial statements. For OncoTherapy Science (TSE:4564), the current Net Margin % is -94.39% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OncoTherapy Science (TSE:4564) Overvalued in 2026?

Based on GuruFocus' analysis, OncoTherapy Science stock appears to be overvalued. The current stock price of 円21.00 is trading 23.2% above its estimated GF Value™ of 円17.04. GuruFocus considers OncoTherapy Science to be Modestly Overvalued.

Key valuation signals for TSE:4564:

Net Margin %: -94.39%
GF Value™: 円17.04 vs. price of 円21.00 (23.2% above fair value)
GF Score™: 50/100 with 1 warning sign

No single metric tells the full story. See the TSE:4564 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OncoTherapy Science Business Description

Industry Healthcare Biotechnology

Comparable Companies TSE:7776 TSE:4596 TSE:4571 TSE:7096 TSE:4896 TSE:3750 TSE:4584 TSE:2370 TSE:2385 TSE:4594 VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges 30O:Germany

Address 11th Floor, Kanagawa Science Park R&D, 3-2-1 Sakado, Kanagawa, Kawasaki, JPN, 213-0012

Website http://www.oncotherapy.co.jp

OncoTherapy Science Inc focuses on cancer-related cells and genes and develops cancer therapy products which include low molecular drugs, antibody drugs, cancer peptide vaccine, and diagnostic medicine in Japan.

50GF Score

Get the complete analysis for TSE:4564

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円21.00

Price

円17.04

GF Value

View TSE:4564 Analysis

See Net Margin % data for all stocks →